PPCB — Propanc Biopharma Cashflow Statement
0.000.00%
- $0.21m
- $1.11m
Annual cashflow statement for Propanc Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -5.76 | -4.74 | -2.03 | -2.66 | -2.66 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 3.19 | 2.68 | 0.44 | 1.05 | 1.08 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.503 | 0.209 | 0.443 | 0.167 | 0.473 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -2.06 | -1.85 | -1.15 | -1.44 | -1.11 |
Capital Expenditures | -0.003 | 0 | — | — | — |
Purchase of Fixed Assets | |||||
Cash from Investing Activities | -0.003 | 0 | — | — | — |
Financing Cash Flow Items | -0.079 | -0.151 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 2.12 | 1.89 | 1.06 | 1.49 | 1.11 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.018 | 0.065 | -0.065 | 0.002 | 0.006 |